Arbutus Biopharma Corporation $ABUS Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lessened its position in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 17.1% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 800,000 shares of the biopharmaceutical company’s stock after selling 165,000 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Arbutus Biopharma were worth $3,632,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Arbutus Biopharma by 290.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company’s stock worth $7,245,000 after purchasing an additional 1,544,070 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Arbutus Biopharma by 63.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,575,941 shares of the biopharmaceutical company’s stock valued at $7,960,000 after purchasing an additional 1,000,000 shares during the period. Two Seas Capital LP grew its holdings in shares of Arbutus Biopharma by 10.3% in the second quarter. Two Seas Capital LP now owns 10,443,317 shares of the biopharmaceutical company’s stock valued at $32,270,000 after purchasing an additional 977,361 shares in the last quarter. Bank of America Corp DE increased its stake in Arbutus Biopharma by 161.4% during the 2nd quarter. Bank of America Corp DE now owns 1,197,655 shares of the biopharmaceutical company’s stock worth $3,701,000 after buying an additional 739,429 shares during the period. Finally, UBS Group AG increased its stake in Arbutus Biopharma by 307.2% during the 3rd quarter. UBS Group AG now owns 774,594 shares of the biopharmaceutical company’s stock worth $3,517,000 after buying an additional 584,386 shares during the period. 43.79% of the stock is currently owned by hedge funds and other institutional investors.

Arbutus Biopharma Trading Down 3.0%

Shares of NASDAQ:ABUS opened at $4.24 on Friday. The firm has a 50 day simple moving average of $4.31 and a 200-day simple moving average of $4.43. Arbutus Biopharma Corporation has a twelve month low of $2.70 and a twelve month high of $5.10. The company has a market capitalization of $815.44 million, a PE ratio of -18.43 and a beta of 0.69.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.00.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.